TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT07392255: An Optimised GA Interventional Trial (Opti-GAIN) to Test if Treatment With CTx001 is Safe and Works for People With Geographic Atrophy (GA)

Sponsor: Complement Therapeutics · Phase: PHASE1/PHASE2 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 75 pts

Competing Trials Overlap

7 Active Trials

Excess Burn Exposure

$1,072,360

Rescue Site Savings

+$705,500

Unlock Full NCT07392255 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07392255 Rescue Dossier →